Aspirin is a highly successful antiplatelet drug & still retains its status as the 'front-line' antiplatelet drug; however, any effective antiplatelet dose of aspirin is associated with an increased risk of bleeding. Hence increased understanding of platelet biology has led to the development of new antiplatelet drugs that are potentially more effective. Aspirin and P2Y12 inhibitors (clopidogrel, prasugrel and ticagrelor) are the most commonly used antiplatelet drugs, either alone or as dual antiplatelet therapy. In this discussion with leading cardiologist Dr. Jagdish Hiremath, we go over a detailed review of newer antiplatelets over aspirin and discuss the overall safety and efficacy.

Aspirin vs. Newer Antiplatelets: What Should You Choose?

Senior Interventional Cardiologist, Ruby Hall Clinic, Pune

Join the Cardio-Renal-Metabolic (CRM) Grand Rounds for an intensive exploration of early CKD detection and SGLT2 inhibition breakthroughs. Our distinguished panel will present practical approaches to identifying CKD markers, analyze a decade of SGLT2 inhibitor evidence, and share strategies for integrated CRM care. This focused session combines the latest clinical data with practical insights, essential for advancing your CRM practice.

Dr. Jagdish Hiremath

1

491

13k

4.8

Upcoming Sessions

Sessions Taken

1k

4.8